Overview

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Status:
RECRUITING
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Compass Therapeutics, Inc
Treatments:
Cisplatin
durvalumab
Gemcitabine